Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LENZ
STRONG SELLLENZ Therapeutics, Inc. · Healthcare · United States · $172M · Avg Vol: $6M/d
COMPANY DESCRIPTION
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for presbyopia, an age-related loss of near vision. It targets a large, underserved patient population with an innovative, non-surgical solution, aiming to offer a more convenient and effective treatment option. LENZ is a specialty ophthalmology biopharma focused on commercializing a potentially first-in-class product for a widespread vision condition.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 15.0M | 0 | 0 | 19.1M | 8.4% | 21.0M | 19.0M | — | -0.5% |
| EPS | -0.30 | -0.42 | -2.74 | -2.34 | -2.85 | — | -3.48 | -4.56 | -3.51 | — |
| Shares | 25.5M | 25.5M | 25.5M | 27.5M | 31.3M | +22.8% | 31.4M | — | — | — |
| Debt | 0 | 0.3M | 0.3M | 1.4M | 0.8M | 48.3% | 0.7M | — | — | — |
| Equity | -14.2M | -24.2M | -92.7M | 204.1M | 284.3M | 39.3% | — | — | — | — |
| Op CF | -5.4M | -4.1M | -60.4M | -59.4M | -69.2M | — | -86.7M | — | — | — |
| Inv CF | -9.0K | -37.0K | -29.6M | -154.5M | -75.7M | — | — | — | — | — |
| Fin CF | 22.8M | 30.3M | 80.7M | 199.0M | 149.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LENZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc.(you) | $172M | 7 | STRONG SELL |
| ALEC | Alector, Inc. | $164M | 5 | STRONG SELL |
| ARMP | Armata Pharmaceuticals, Inc. | $171M | 4 | STRONG SELL |
| GLSI | Greenwich LifeSciences, Inc. | $191M | 8 | STRONG SELL |
| 0HIY.L | Atara Biotherapeutics, Inc. | $161M | 10 | STRONG SELL |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $164M | 10 | STRONG SELL |
| HUMA | Humacyte, Inc. | $168M | 2 | STRONG SELL |
| GNLX | Genelux Corporation | $130M | 7 | STRONG SELL |
| IVVD | Invivyd, Inc. | $180M | 12 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $222M | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%